| Product | Target Antigen | Isotype | Indication |
Research
Preclinical
IND enabling
Phase I
Phase Ib
|
|---|---|---|---|---|
| MOV18 IgE | FR alpha | IgE | Platinum Resistant Ovarian Cancer |
|
| FR alpha | IgE | Endometrial, TNBC, NSCLC |
|
|
| EPS 401 | EGRFR | IgA | Colorectal, NSCLC |
|
| Product 3 | TBA | IgE | TBA |
|
MOv18 IgE
Lead candidate MOv18 IgE is currently in a phase Ib trial in platinum-resistant ovarian cancer (PROC). It is the world’s first IgE therapeutic to enter the clinic and targets folate receptor ⍺ (FR⍺) a commercially validated and highly tumour-specific antigen. The phase I study demonstrated a good safety profile with early efficacy signals seen.
Learn more about MOv18 IgE
EPS 401
EPS 401 is an anti-EGFR IgA and our lead IgA candidate. It binds to the highly validated antigen EGFR and was constructed using our proprietary IgA 3.0 platform. EPS 401 is expected to enter clinic in 2027.
Further Products
A range of further products based on our antibody platforms are in the research stage.